These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 4666638

  • 1. [Results of psychometic tests in 23 patients with Parkinson's disease after 6 months treatment with L-dopa].
    Barbizet J, Duizabo P, Pasquier M.
    Rev Neurol (Paris); 1972 Aug; 127(2):311-3. PubMed ID: 4666638
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)].
    Mazza C, Buffatti PF, Bazzan A, Lion P.
    Fracastoro; 1970 Aug; 63(5):768-73. PubMed ID: 5519378
    [No Abstract] [Full Text] [Related]

  • 5. [Silent period in patients with Parkinson's disease treated with L-Dopa].
    Palao Sánchez A.
    Arch Neurobiol (Madr); 1973 Aug; 36(1):47-56. PubMed ID: 4706780
    [No Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ, Papadopoulos NM.
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract] [Full Text] [Related]

  • 7. [The treatment of Parkinson's disease with L-dopa].
    Dalle Ore G, Bricolo A, Robotti E, Bazzan A, Mazza C.
    Policlinico Prat; 1970 Apr 20; 77(16):509-24. PubMed ID: 5443873
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G, Castaigne P, Lhermitte F, Beck H, Guillard A, Marteau R, Pepin B, Rondot P, Raphy B.
    Rev Neurol (Paris); 1970 Feb 20; 122(2):89-102. PubMed ID: 4931719
    [No Abstract] [Full Text] [Related]

  • 9. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA, Vanna S, Beasley B, Chambers R, Vogel WH.
    J Lab Clin Med; 1971 Feb 20; 77(2):319-25. PubMed ID: 5540775
    [No Abstract] [Full Text] [Related]

  • 10. [L-dopa in the treatment of Parkinson's disease. Preliminary report].
    Poch GF.
    Prensa Med Argent; 1969 Oct 24; 56(34):1629-32. PubMed ID: 5405572
    [No Abstract] [Full Text] [Related]

  • 11. The effect of L-dopa treatment on the speech of patients with Parkinson's disease.
    Audelman JU, Hoel RL, Lassman FM.
    Neurology; 1970 Apr 24; 20(4):410-1. PubMed ID: 5535064
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of Parkinson's syndrome with L-dopa. In operated and nonoperated cases].
    Pimenta Ada M, Friguglietti DJ.
    Rev Bras Med; 1971 Sep 24; 28(9):481-96. PubMed ID: 5139650
    [No Abstract] [Full Text] [Related]

  • 13. [Utility of L-dopa in the treatment of Parkinson's disease and parkinsonism-like diseases].
    Herskovits E, Matera R, Gacitua EF.
    Medicina (B Aires); 1972 Sep 24; 32(1):10-4. PubMed ID: 5019629
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Treatment of Parkinson's syndrome with L-dopa].
    Ljung O.
    Lakartidningen; 1972 Jun 07; 69(24):2940-4. PubMed ID: 5037135
    [No Abstract] [Full Text] [Related]

  • 17. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism].
    Gerstenbrand F, Grünberger J, Schubert H.
    Nervenarzt; 1973 Aug 07; 44(8):428-33. PubMed ID: 4733895
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of 3, 4-dihydroxyphenylalanine (Dopa) in Parkinson's disease.
    Van Woert MH.
    Conn Med; 1970 Jun 07; 34(6):401-5. PubMed ID: 5431103
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.